Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Stock Information for Interpace Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Interpace Biosciences Inc.

Vyant Bio Provides Update on Winddown Activities
Vyant Bio Provides Update on Winddown Activities
Vyant Bio Announces Stockholder Approval of Plan of Dissolution
Vyant Bio Announces Completion of StemoniX Asset Sale
Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders
Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders
Vyant Bio Announces Adjournment of Special Meeting of Stockholders
Vyant Bio Announces Adjournment of Special Meeting of Stockholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.